This website uses cookies to enhance the user experience.
STANDARD BIO AS

STANDARD BIO AS996 515 427

Research
Limited company
Televegen 2 3802 BØ I TELEMARK, Norge

STANDARD BIO AS

Standard Bio

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

Chairman of the board
Years since formation
14 years
since Feb 3, 2011
Type
Limited company
VAT registered
Yes
Number of employees
8

Ownership

Number of shares and share classes
39,109,602
2 share classes
Total number of shareholders
165
58 companies, 107 persons
Belongs to group of

Financials

Total operating income 2024
20,435,267
NOK
Annual total result 2024
-16,799,344
NOK
Total equity 2024
19,574,018
NOK
Last update: Jul 2, 2025

Management

Management / administration

NameRoleShares
Managing Director/CEO
1.02 %
directly

Board

NameRoleShares
Chairman
24.87 %
indirectly
Board Member-
Board Member-
Board Member
1.17 %
indirectly

Others

NameRoleShares
Auditor-
S
STATEMENT AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Chairman
24.87 %
indirectly
-
7.92 %
indirectly
-
1.4 %
directly < 0.01 %
indirectly 1.39 %
Board Member
1.17 %
indirectly
Managing Director/CEO
1.02 %
directly
Last update: Apr 13, 2023

Ownership

Company shareholders

NameShare classTotal number of sharesShare
C
COMMERCOR AS
Ordinary shares
9,716,640
24.84 %
Ordinary shares
3,623,756
9.27 %
Ordinary shares
3,237,098
8.28 %
C
COMMERCOR AS
Preference shares
3,185,432
8.14 %
B
BAGGINS AS
Ordinary shares
2,773,818
7.09 %
S
SUMMEN AS
Ordinary shares
2,692,235
6.88 %
Preference shares
2,027,093
5.18 %
B
BAGGINS AS
Preference shares
2,027,093
5.18 %
Preference shares
2,027,093
5.18 %
S
SUMMEN VENTURE AS
Ordinary shares
1,186,836
3.03 %
B
BAGGINS VENTURE AS
Ordinary shares
975,877
2.5 %
C
CLAWBACK AS
Ordinary shares
878,434
2.25 %
S
SKALTOR AS
Ordinary shares
529,570
1.35 %
C
CAPTUREBANK HOLDING AS
Ordinary shares
488,996
1.25 %
M
MARCHFIRST NORWAY AS
Ordinary shares
428,819
1.1 %
Ordinary shares
400,459
1.02 %
C
CHRISNIC CAPITAL AS
Ordinary shares
285,085
0.73 %
F
FAMARA HOLDING AS
Ordinary shares
257,661
0.66 %
H
HUITFELDT-KAAS AS
Ordinary shares
200,000
0.51 %
K
KRAKR AS
Ordinary shares
199,816
0.51 %
Ordinary shares
198,446
0.51 %
Ordinary shares
167,363
0.43 %
M
MAHA NORGE AS
Ordinary shares
143,078
0.37 %
Ordinary shares
112,857
0.29 %
Ordinary shares
112,099
0.29 %
Ordinary shares
111,773
0.29 %
T
Ordinary shares
92,435
0.24 %
Preference shares
68,452
0.18 %
C
CENTAURUS AS
Ordinary shares
61,538
0.16 %
O
OVE LERDAHL AS
Ordinary shares
57,318
0.15 %
S
SCAN-AMERICAN TRADING CO AS
Ordinary shares
54,793
0.14 %
Ordinary shares
54,694
0.14 %
G
GRÜNDERSEN AS
Ordinary shares
53,793
0.14 %
D
DIN MENTOR AS
Ordinary shares
46,643
0.12 %
A
ACCRUITY AS
Ordinary shares
46,480
0.12 %
Ordinary shares
46,365
0.12 %
Ordinary shares
46,365
0.12 %
Ordinary shares
46,365
0.12 %
V
VALTOR AS
Ordinary shares
43,634
0.11 %
Ordinary shares
42,944
0.11 %
M
MAFELA AS
Ordinary shares
40,424
0.1 %
Preference shares
34,550
0.09 %
S
SMÅSTØLANE AS
Ordinary shares
26,613
0.07 %
A
ALYLA AS
Ordinary shares
25,353
0.06 %
Ordinary shares
24,033
0.06 %
Ordinary shares
21,981
0.06 %
T
TJELD AS
Ordinary shares
19,327
0.05 %
F
FIRST PARTNERS HOLDING 8 AS
Ordinary shares
13,396
0.03 %
I
IMOVEST AS
Ordinary shares
13,106
0.03 %
Ordinary shares
12,000
0.03 %
Ordinary shares
11,927
0.03 %
B
BENARES AS
Ordinary shares
9,964
0.03 %
H
HURD AS
Ordinary shares
9,557
0.02 %
Ordinary shares
8,400
0.02 %
U
UTGARD AS
Ordinary shares
7,782
0.02 %
Ordinary shares
6,440
0.02 %
S
SARAFINA AS
Ordinary shares
4,937
< 0.01 %
A
AKROBAT INVEST AS
Ordinary shares
4,868
< 0.01 %
Ordinary shares
4,636
< 0.01 %
Ordinary shares
4,636
< 0.01 %
G
GREINA TREFELLING AS
Ordinary shares
3,835
< 0.01 %
Ordinary shares
3,653
< 0.01 %
Ordinary shares
3,600
< 0.01 %
Ordinary shares
3,068
< 0.01 %
Ordinary shares
3,017
< 0.01 %
Ordinary shares
3,000
< 0.01 %
S
STANDARD BIO AS
Ordinary shares
2,737
< 0.01 %
M
MUTLE AS
Ordinary shares
2,595
< 0.01 %
L
LANGEFINNE AS
Ordinary shares
2,594
< 0.01 %
V
VANN & ENERGI TEKNIKK AS
Ordinary shares
2,301
< 0.01 %
S
STOKNES FUTURES AS
Ordinary shares
2,142
< 0.01 %
M
MOLDBAKKEN AS
Ordinary shares
1,994
< 0.01 %
Ordinary shares
1,994
< 0.01 %
T
THEMAR EIENDOM AS
Ordinary shares
1,340
< 0.01 %
Ordinary shares
1,334
< 0.01 %
C
CORTON AS
Ordinary shares
1,250
< 0.01 %
Ordinary shares
1,244
< 0.01 %
Ordinary shares
1,142
< 0.01 %
Ordinary shares
1,035
< 0.01 %
Ordinary shares
999
< 0.01 %
Ordinary shares
730
< 0.01 %
Ordinary shares
702
< 0.01 %
Ordinary shares
557
< 0.01 %
Ordinary shares
533
< 0.01 %
Ordinary shares
525
< 0.01 %
Ordinary shares
499
< 0.01 %
Ordinary shares
486
< 0.01 %
Ordinary shares
445
< 0.01 %
Ordinary shares
434
< 0.01 %
Ordinary shares
387
< 0.01 %
Ordinary shares
360
< 0.01 %
Ordinary shares
347
< 0.01 %
H
HBT SUPPORT AS
Ordinary shares
336
< 0.01 %
Ordinary shares
317
< 0.01 %
Ordinary shares
289
< 0.01 %
F
FJORD-PARTNERS AS
Ordinary shares
272
< 0.01 %
Ordinary shares
227
< 0.01 %
Ordinary shares
217
< 0.01 %
Ordinary shares
157
< 0.01 %
Ordinary shares
157
< 0.01 %

Shares owned by the STANDARD BIO AS

NameShare classTotal number of sharesShare
D
DRYSEP AS
Ordinary shares
1,000,000
100 %
B
BIONÉR AS
Ordinary shares
2,110,000
100 %
U
UPCYCLE TECHNOLOGIES AS
Ordinary shares
30,000
100 %
E
ERA BIOCARBON AS
Ordinary shares
30,000
100 %
C
CRUDA AS
Ordinary shares
150,000
50 %
G
GAMKINN BIO AS
Ordinary shares
12,000
40 %
S
STANDARD BIO AS
Ordinary shares
2,737
< 0.01 %
Last update: Jun 2, 2025

Group structure

  • Total operating income 2024: NOK 20,435,267
    Operating profit 2024: NOK -6,566,734
    Employees: 8

Financials

in NOK

Summary

Year2024202320222021
Total operating income
20,435,267
25,114,069
8,012,262
6,775,948
Annual Total Result
-16,799,344
-2,593,977
-7,427,038
-9,253,171
Total assets
41,101,712
39,160,932
25,170,613
37,923,688
Total liabilities
21,527,694
19,089,063
22,914,986
38,241,019
Total equity
19,574,018
20,071,869
2,255,627
-317,331

P&L

Year2024202320222021
Total operating income
20,435,267
25,114,069
8,012,262
6,775,948
Total operating costs
27,002,001
26,007,925
14,577,381
14,968,037
Operating result
-6,566,734
-893,856
-6,565,119
-8,192,089
Financial income/costs
-10,232,610
-1,700,121
-861,919
-1,061,082
Profit before tax
-16,799,344
-2,593,977
-7,427,038
-9,253,171
Total tax & extraordinary income/cost
0
0
0
0
Annual Total Result
-16,799,344
-2,593,977
-7,427,038
-9,253,171

Balance overview

Year2024202320222021
Total fixed assets
26,308,300
33,469,409
24,114,583
21,810,360
Total current assets
14,793,412
5,691,523
1,056,030
16,113,327
Total assets
41,101,712
39,160,932
25,170,613
37,923,688
Short term debt
16,533,246
13,358,428
16,230,371
30,578,872
Long term debt
4,994,448
5,730,635
6,684,615
7,662,147
Total liabilities
21,527,694
19,089,063
22,914,986
38,241,019
Contributed capital
19,574,018
20,071,869
13,521,673
21,610,672
Retained earnings
0
0
-11,266,046
-21,928,003
Total equity
19,574,018
20,071,869
2,255,627
-317,331
Total equity and liabilities
41,101,712
39,160,932
25,170,613
37,923,688

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology